UK govt proposes fifth NICE work program

8 February 2001

The UK Department of Health has proposed that, following consultationwith key stakeholders, the NICE's fifth work program should examine:

- Novartis' Glivec (STI-571) for the predominant form of chronic myeloid leukemia. The DoH says it may provide an important new option for treatment, although "some uncertainties remain;" - thrombolytic drugs for early initiation in acute heart attack; - Alza/Schering-Plough's Caelyx (liposomal doxorubicin for injection) for the treatment of ovarian cancer; and - photodynamic therapy for age-related macular degeneration.

Also proposed for inclusion in the new work program are surgical treatments for morbidly obese people, computerized cognitive behavior therapy for depression and/or anxiety, hip resurfacing for younger people and ultrasonic locating devices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight